Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $23.3 million.

  • Orchestra BioMed Holdings' Net Cash Flow rose 112954.55% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 15137.12%. This contributed to the annual value of -$8.3 million for FY2024, which is 17701.16% down from last year.
  • Orchestra BioMed Holdings' Net Cash Flow amounted to $23.3 million in Q3 2025, which was up 112954.55% from $401000.0 recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Net Cash Flow registered a high of $77.6 million during Q2 2022, and its lowest value of -$77.2 million during Q4 2022.
  • Over the past 4 years, Orchestra BioMed Holdings' median Net Cash Flow value was $389000.0 (recorded in 2024), while the average stood at $2.1 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Net Cash Flow crashed by 56437.1% in 2024 and then soared by 112954.55% in 2025.
  • Orchestra BioMed Holdings' Net Cash Flow (Quarter) stood at -$77.2 million in 2022, then skyrocketed by 114.87% to $11.5 million in 2023, then tumbled by 129.13% to -$3.3 million in 2024, then skyrocketed by 795.66% to $23.3 million in 2025.
  • Its last three reported values are $23.3 million in Q3 2025, $401000.0 for Q2 2025, and -$3.9 million during Q1 2025.